Login to Your Account

Clinic roundup

Thursday, January 9, 2014

Mast Therapeutics Inc., of San Diego, provided an update on the status of EPIC, its pivotal Phase III study of MST-188 in sickle cell disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription